Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17531
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHuynh, Jennifer-
dc.contributor.authorEtemadi, Nima-
dc.contributor.authorHollande, Frédéric-
dc.contributor.authorErnst, Matthias-
dc.contributor.authorBuchert, Michael-
dc.date2017-06-01-
dc.date.accessioned2018-04-25T23:51:10Z-
dc.date.available2018-04-25T23:51:10Z-
dc.date.issued2017-08-
dc.identifier.citationSeminars in cancer biology 2017; 45: 13-22-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/17531-
dc.description.abstractIntercellular communication between tumor cells, immune cells and the stroma characterises the tumor microenvironment, which is instrumental for establishing the ecological niche that fosters tumor growth and metastasis. While tumor cell intrinsic STAT3 signaling provides a crucial axis to support cell proliferation and survival, it also regulates many activities of the non-transformed cells that collectively make up the tumor microenvironment. Accordingly, excessive activation of STAT3 is a hallmark of many malignancies, and often occurs in response to cytokines of the IL-6 and IL-10 families. However, tumor extrinsic STAT3 signaling also regulates the effector function of tumor-associated immune and stromal cells, which support the growth of tumors by suppressing the host's anti-tumor immune response. Given that STAT3 mediates tumorigenic effects in many cell types, the molecular players of STAT3 signaling and its upstream JAK kinases provide viable therapeutic targets for the treatment of cancer. Here we provide an update on novel insights into the role of STAT3 in immune suppression and describe current therapeutic strategies that target the JAK/STAT3 signaling axis for the treatment of malignancies.-
dc.language.isoeng-
dc.subjectImmunosuppression-
dc.subjectImmunotherapy-
dc.subjectJanus kinase (JAK)-
dc.subjectSignal transducer and activator of transcription 3 (STAT3)-
dc.subjectTumor development-
dc.titleThe JAK/STAT3 axis: A comprehensive drug target for solid malignancies.-
dc.typeJournal Article-
dc.identifier.journaltitleSeminars in cancer biology-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia-
dc.identifier.affiliationDepartment of Pathology, The University of Melbourne, Victorian Comprehensive Cancer Centre, Grattan St, Parkville Victoria, Australia-
dc.identifier.doi10.1016/j.semcancer.2017.06.001-
dc.identifier.orcid0000-0002-6399-1177-
dc.identifier.pubmedid28647610-
dc.type.austinJournal Article-
dc.type.austinReview-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.